Glaxo Drug Quickly Suppresses HIV in a Human Clinical Trial
February 25, 2005
At the 12th Conference on Retroviruses and Opportunistic Infections, a GlaxoSmithKline researcher presented data on the progress being made on a new experimental HIV drug.
In a controlled study of 31 patients, the drug suppressed HIV by about 98 percent after just 10 days of treatment, said James Demarest, leader of Glaxo's clinical virology department in Research Triangle Park, N.C. Demarest said the drug, called 873140, should enter Phase III efficacy studies involving hundreds of patients later in the year.
The drug blocks HIV from using the CCR5 receptors to enter human cells. The drug compound was licensed from Japan-based Ono Pharmaceutical Co., which retains certain Asian marketing rights. The GSK drug received fast-track status from the Food and Drug Administration. Pfizer Inc. and Schering-Plough Corp. are developing similar drugs.
Wall Street Journal
02.25.2005; Marilyn Chase
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.